KERX / Keryx Biopharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

KERX / Keryx Biopharmaceuticals, Inc. 15-12G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-30929 KERYX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specif

KERX / Keryx Biopharmaceuticals, Inc. POS462B

As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS462B

As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS462B

As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POSASR

POSASR As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS AM

POS AM 1 d674391dposam.htm POS AM As filed with the Securities and Exchange Commission on December 13, 2018 Registration No. 333-111143 Registration No. 333-113654 Registration No. 333-114593 Registration No. 333-119376 Registration No. 333-126494 Registration No. 333-130809 Registration No. 333-133051 Registration No. 333-161607 Registration No. 333-171517 Registration No. 333-186332 Registration

KERX / Keryx Biopharmaceuticals, Inc. POS AM

As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS AM

As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS AM

POS AM As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS AM

POS AM As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS AM

POS AM As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS AM

As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS AM

POS AM As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS AM

POS AM As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. POS AM

POS AM As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. S-8 POS

As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. S-8 POS

S-8 POS 1 d677102ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on December 13, 2018 Registration No. 333-55006 Registration No. 333-119377 Registration No. 333-133052 Registration No. 333-145003 Registration No. 333-165710 Registration No. 333-190358 Registration No. 333-210116 Registration No. 333-213267 Registration No. 333-226005 UNITED STATES SECURITIES AND EXCHANGE C

KERX / Keryx Biopharmaceuticals, Inc. S-8 POS

S-8 POS 1 d677102ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on December 13, 2018 Registration No. 333-55006 Registration No. 333-119377 Registration No. 333-133052 Registration No. 333-145003 Registration No. 333-165710 Registration No. 333-190358 Registration No. 333-210116 Registration No. 333-213267 Registration No. 333-226005 UNITED STATES SECURITIES AND EXCHANGE C

KERX / Keryx Biopharmaceuticals, Inc. S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. S-8 POS

S-8 POS 1 d677102ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on December 13, 2018 Registration No. 333-55006 Registration No. 333-119377 Registration No. 333-133052 Registration No. 333-145003 Registration No. 333-165710 Registration No. 333-190358 Registration No. 333-210116 Registration No. 333-213267 Registration No. 333-226005 UNITED STATES SECURITIES AND EXCHANGE C

KERX / Keryx Biopharmaceuticals, Inc. S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

KERX / Keryx Biopharmaceuticals, Inc. S-8 POS

S-8 POS 1 d677102ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on December 13, 2018 Registration No. 333-55006 Registration No. 333-119377 Registration No. 333-133052 Registration No. 333-145003 Registration No. 333-165710 Registration No. 333-190358 Registration No. 333-210116 Registration No. 333-213267 Registration No. 333-226005 UNITED STATES SECURITIES AND EXCHANGE C

KERX / Keryx Biopharmaceuticals, Inc. S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 13, 2018 Registration No.

Amended and Restated Bylaws of Keryx Biopharmaceuticals, Inc.

EX-3.2 Table of Contents Exhibit 3.2 BYLAWS OF KERYX BIOPHARMACEUTICALS, INC. (a Delaware corporation) Adopted as of December 12, 2018 Table of Contents TABLE OF CONTENTS Page ARTICLE I. IDENTIFICATION; OFFICES 1 SECTION 1. NAME 1 SECTION 2. PRINCIPAL AND BUSINESS OFFICES 1 SECTION 3. REGISTERED AGENT AND OFFICE 1 SECTION 4. PLACE OF KEEPING CORPORATE RECORDS 1 ARTICLE II. STOCKHOLDERS 1 SECTION 1

Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc.

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KERYX BIOPHARMACEUTICALS, INC. FIRST: The name of the Corporation is Keryx Biopharmaceuticals, Inc. (hereinafter the “Corporation”). SECOND: The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, 19801. The name of its registered agent at that a

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Submission of Matters to a Vote of Security Holders

8-K 1 d670842d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction

KERX / Keryx Biopharmaceuticals, Inc. / Baupost Group LLC/MA - NONE Activist Investment

SC 13D/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Keryx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 492515101 (CUSIP Number) Seth A. Klarman, The Baupost Group, L.L.C. 10 St. James Avenue, Suite 1700, Boston, Massachusetts 02116 Phone :

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 December 3, 2018 Dear Fellow Keryx Stockholder: I am writing on behalf of the Board of Directors of Keryx Biopharmaceuticals, Inc. (“Keryx”) to

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 1 d666061d425.htm 425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeu

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Akebia Therapeutics, Inc. Commission File No.: 001-36352 Date: November 29, 2018 Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Propose

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics Leading proxy advisory fi

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Akebia Therapeutics, Inc. Commission File No.: 001-36352 Date: November 29, 2018 Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote “FOR” Proposed Merger with Keryx Ake

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Merger of Equals to Create a Financially Stronger Company Focused on the Development and Commercialization of Therapeutics for Patients with Chronic Kidney Disease (NASDAQ: AKBA) (NASDAQ: KERX) Filed by Keryx Biopharmaceuticals, Inc.

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 November 20, 2018 Dear Fellow Keryx Stockholder: I am writing on behalf of the Board of Directors of Keryx Biopharmaceuticals, Inc. (“Keryx

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Creating a Financially Strong Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease November 16, 2018 Filed by Akebia Therapeutics, Inc.

AKBA / Akebia Therapeutics, Inc. 8-K (Prospectus)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2018 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Co

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 FOR IMMEDIATE RELEASE Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company Adrian Adams To Serve as I

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Akebia Therapeutics, Inc. Commission File No.: 001-36352 Date: November 15, 2018 FOR IMMEDIATE RELEASE Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company Adr

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Akebia Therapeutics, Inc. Commission File No.: 001-36352 Date: November 13, 2018 FOR IMMEDIATE RELEASE Akebia Therapeutics Sends Letter to Shareholders Recommends Shareholders Vote “FOR” the Propos

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Akebia Therapeutics, Inc. Commission File No.: 001-36352 Date: November 13, 2018 The following e-mail was sent to all employees of Akebia Therapeutics, Inc., on November 13, 2018. Dear HIFsters, I

Quarterly Report - 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-3

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 1 d612915d425.htm 425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30939 November 9, 2018 Dear Fellow Keryx Stockholder: As Chairperson of the Board of Keryx Biopharmaceuticals, Inc. (“Keryx

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results • Third quarter 2018 total revenues of $28.0 million including net

Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results • Third quarter 2018 total revenues of $28.0 million including net U.S. Auryxia® (ferric citrate) product sales of $26.6 million, a 96 percent increase compared to the third quarter of 2017 • Approximately 47,500 Auryxia Prescriptions were written in the third quarter of 2018, nearly double the number repo

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation

First Supplemental Indenture dated November 8, 2018, by and between Keryx Biopharmaceuticals, Inc. and The Bank of New York Mellon Trust Company, N.A. to the Indenture dated as of May 9, 2018.

Exhibit 10.1 FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated as of November 8, 2018, between KERYX BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a national banking association, as Trustee under the Indenture referred to below (in such capacity, the “Trustee”). W I T N E S

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-30929 KERYX BIOPHARMA

Amendment to Employment Agreement by and between Keryx Biopharmaceuticals, Inc. and Jodie Morrison dated as of October 31, 2018 (incorporated by reference to Exhibit 10.2 to Keryx Biopharmaceuticals, Inc.’s Quarterly Report on Form 10-Q, filed on November 8, 2018)

Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”) is made and entered into this 2nd day of November, 2018 (the “Effective Date”) by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Jodie Morrison (“Executive”) (each a “Party” and collectively, the “Parties”) BACKGROUND WHEREAS, the Company currently employ

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 NASDAQ: AKBA NASDAQ: KERX Merger of Equals to Create a Financially Stronger Company Focused on the Development and Commercialization of The

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 1 d599390d425.htm 425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Akebia Therapeutics, Inc. Commission File No.: 001-36352 Date: October 30, 2018 FOR IMMEDIATE RELEASE Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Ke

KERX / Keryx Biopharmaceuticals, Inc. DEFM14A

DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Strategic Fit + Financial Strength Merger Creates a Leading Fully Integrated Biopharmaceutical in Renal Disease October 29, 2018 Filed by Akebia Therapeutics, Inc.

Entry into a Material Definitive Agreement, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 24, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Commis

KERX / Keryx Biopharmaceuticals, Inc. FORM 8-K (Prospectus)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 24, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease October 2, 2018 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Date: O

First Amendment to Agreement and Plan of Merger dated October 1, 2018, by and among Akebia Therapeutics, Inc., Alpha Therapeutics Merger Sub Inc. and Keryx Biopharmaceuticals, Inc.

EX-2.1 Exhibit 2.1 FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER This FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of October 1, 2018 is entered into by and among Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”); Alpha Therapeutics Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Akebia (“Merger Sub”); and Keryx Biopharmaceutic

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 1, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Com

First Amendment to Agreement and Plan of Merger, dated as of October 1, 2018, by and among Akebia Therapeutics, Inc., Alpha Therapeutics Merger Sub, Inc., and Keryx Biopharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed on October 1, 2018)

EX-2.1 Exhibit 2.1 FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER This FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of October 1, 2018 is entered into by and among Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”); Alpha Therapeutics Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Akebia (“Merger Sub”); and Keryx Biopharmaceutic

KERX / Keryx Biopharmaceuticals, Inc. 8-K (Prospectus)

425 1 d627701d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 1, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction o

First Amendment to Agreement and Plan of Merger dated October 1, 2018

EX-2.1 Exhibit 2.1 FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER This FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of October 1, 2018 is entered into by and among Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”); Alpha Therapeutics Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Akebia (“Merger Sub”); and Keryx Biopharmaceutic

AKBA / Akebia Therapeutics, Inc. 8-K (Prospectus)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 1, 2018 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of incorporation) (Comm

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease September 14, 2018 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 193

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease September 14, 2018 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Date

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease September 6, 2018 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease September 6, 2018 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commi

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Akebia Therapeutics, Inc. Commission File No.: 001-36352 Date: August 9, 2018 Corporate Conference Call Wednesday, 8th August 2018 Corporate Conference Call Wednesday, 8th August 2018 Opening Remar

Retention Bonus Award Agreement with Scott A. Holmes dated May 1, 2018.

Exhibit 10.8 KERYX BIOPHARMACEUTICALS, INC. RETENTION BONUS AWARD AGREEMENT This Retention Bonus Award Agreement (this “Agreement”) is made and entered into on May 1, 2018 (the “Effective Date”), between Keryx Biopharmaceuticals, Inc. (the “Company”) and Scott Holmes (“Employee”). WHEREAS, Employee occupies a key position with the Company and in order to ensure the continued effective conduct of t

Amendment No. 1 to the Product Manufacture and Supply and Facility Construction Agreement, dated May 5, 2018, by and between Keryx Biopharmaceuticals, Inc. and BioVectra Inc. (incorporated by reference to Exhibit 10.6 to Keryx Biopharmaceuticals, Inc.’s Quarterly Report on Form 10-Q, filed on August 9, 2018)

Exhibit 10.6 AMENDMENT NO. 1 TO PRODUCT MANUFACTURE AND SUPPLY AND FACILITY CONSTRUCTION AGREEMENT This Amendment No. 1 to the Product Manufacture and Supply and Facility Construction Agreement (“Amendment No. 1”) is made and entered into as of April 20, 2018 (the “Amendment No. 1 Effective Date”) by and between BioVectra Inc., with its registered offices at 11 Aviation Avenue, Charlottetown, PEI,

KERX / Keryx Biopharmaceuticals, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-30929 KERYX BIOPHARMACEUTI

Retention Bonus Award Agreement with John F. Neylan dated May 1, 2018.

Exhibit 10.9 KERYX BIOPHARMACEUTICALS, INC. RETENTION BONUS AWARD AGREEMENT This Retention Bonus Award Agreement (this “Agreement”) is made and entered into on May 1, 2018 (the “Effective Date”), between Keryx Biopharmaceuticals, Inc. (the “Company”) and John F. Neylan, M.D. (“Employee”). WHEREAS, Employee occupies a key position with the Company and in order to ensure the continued effective cond

Retention Bonus Award Agreement with Christine Carberry dated May 1, 2018.

Exhibit 10.10 KERYX BIOPHARMACEUTICALS, INC. RETENTION BONUS AWARD AGREEMENT This Retention Bonus Award Agreement (this “Agreement”) is made and entered into on May 1, 2018 (the “Effective Date”), between Keryx Biopharmaceuticals, Inc. (the “Company”) and Christine Carberry (“Employee”). WHEREAS, Employee occupies a key position with the Company and in order to ensure the continued effective condu

Agenda Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Opening Remarks Jodie Morrison, Interim CEO Business Highlights Scott Holmes, CFO Question & Answer All

EX-99.2 KERYX 2Q18 Financial results August 8, 2018 Exhibit 99.2 Agenda Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Opening Remarks Jodie Morrison, Interim CEO Business Highlights Scott Holmes, CFO Question & Answer All Forward-Looking Statements Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Some of the statements included in

Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results

EX-99.1 2 d604908dex991.htm EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results • Second quarter 2018 total revenues of $25.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $24.1 million; a 71 percent increase compared to the second quarter of 2017 • Approximately 42,500 Auryxia Prescriptions were written in the second quarter of 20

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 d604908d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Commissio

Loan and Security Agreement dated July 18, 2018, between Keryx Biopharmaceuticals, Inc. and Silicon Valley Bank, filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on July 20, 2018 (File No. 000-30929), and incorporated herein by reference.

EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of July 18, 2018 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and KERYX BIOPHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follo

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease July 11, 2018 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 000-30929 Subject Company: Keryx Biopharmaceuticals, Inc. Comm

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease July 11, 2018 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commissio

Submission of Matters to a Vote of Security Holders

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (

KERX / Keryx Biopharmaceuticals, Inc. S-8

S-8 1 d809910ds8.htm S-8 As filed with the Securities and Exchange Commission on June 29, 2018 REGISTRATION NO. 333 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT under the SECURITIES ACT OF 1933 KERYX BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 13-4087132 (State or Other Jurisdiction of Incorpo

Keryx Biopharmaceuticals, Inc. 2018 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to Keryx Biopharmaceuticals, Inc.’s Registration Statement on Form S-8, filed on June 29, 2018)

EX-99.1 Exhibit 99.1 KERYX BIOPHARMACEUTICALS, INC. 2018 EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Keryx Biopharmaceuticals, Inc. 2018 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee

KERX / Keryx Biopharmaceuticals, Inc. / Baupost Group LLC/MA - NONE Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Keryx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 492515101 (CUSIP Number) Seth A. Klarman, The Baupost Group, L.L.C. 10 St. James Avenue, Suite 1700, Boston, Massachusetts 02116 Phone : (617) 210-8300 (Name, Ad

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease June 28, 2018 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmacuticals, Inc. Commission

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmacuticals, Inc. Commission File No.: 000-30929 Date: June 28, 2018 Page 1 of 4 Akebia Employee “Frequently Asked Questions” Document 1. What are the potential benefits of the combination? • The merger of Akebia and Keryx creates a renal-focused

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease June 28, 2018 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopahrmaceuticals, Inc. Commissio

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Date: June 28, 2018 Clinical Study Sites – Letter from Akebia The following is a copy of a letter sent by Akebia Therapeutics, Inc. to its clinical partners. Dear [Clinical Partner / INSERT] This m

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporations: Akebia Therapeutics, Inc. Commission File No.: 001-36352 Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmacuticals, Inc. Commission File No.: 000-30929 Date: June 28, 2018 Vendor Letter from Akebia The following is a copy of a letter sent by Akebia Therapeutics, Inc. to its vendors. Dear [Vendor / INSERT] This morning, we made the announcement that

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 The following is an email sent by Keryx Biopharmaceuticals, Inc.’s Interim Chief Executive Officer to Keryx’s employees: I’m writing with s

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopahrmaceuticals, Inc. Commission File No.: 000-30929 Date: June 28, 2018 Page 1 of 4 Akebia Employee Letter The following is a copy of a letter sent by Akebia Therapeutics, Inc.’s President and Chief Executive Officer to Akebia’s employees. Thursday,

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 Date: June 28, 2018 Akebia Therapeutics and Keryx Biopharmaceuticals Joint Corporate Conference Call Thursday, June 28th 2018 Akebia Therapeutics and Keryx Biopharmaceuticals Conference Call Thursd

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 The following is a copy of a letter sent by Keryx Biopharmaceuticals, Inc. to its clinical partners. Dear [Clinical Partner / INSERT] This

AKBA / Akebia Therapeutics, Inc. 425 (Prospectus)

425 Filed by Akebia Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 Commission File No.: 001-36352 Subject Company: Keryx Biopahrmaceuticals, Inc. Commission File No.: 000-30929 Date: June 28, 2018 The following are social media communications by Akebia Therapeutics, Inc. (“Akebia”) that discuss the proposed merger of Akebia and Keryx Biopharmaceuticals, Inc. Social Media

KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

425 1 d660504d425.htm 425 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals, Inc. Commission File No.: 000-30929 The following is a copy of a letter sent by Keryx Biopharmaceuticals, Inc. to its strategic partners. Dear [PARTNER],

Amendment to Amended and Restated Bylaws, dated June 27, 2018.

EX-3.1 Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF KERYX BIOPHARMACEUTICALS, INC. Article 8 of the Amended and Restated Bylaws of Keryx Biopharmaceuticals, Inc. is hereby amended by adding the following new Section 8.06: 8.06 Exclusive Jurisdiction of Delaware Courts. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the

Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease Expects to Capture Significant Operating and Product Port

EX-99.3 7 d628548dex993.htm EX-99.3 Exhibit 99.3 Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease Expects to Capture Significant Operating and Product Portfolio Synergies, Accelerating Revenue Growth and Creating Shareholder Value Consolidates an FDA-Appro

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

8-K 1 d628548d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Inc

Agreement and Plan of Merger, dated as of June 28, 2018, by and among Akebia Therapeutics, Inc., Alpha Therapeutics Merger Sub Inc. and Keryx Biopharmaceuticals, Inc. *

EX-2.1 The Agreement and Plan of Merger (the “Agreement”) contains representations, warranties and covenants that were made only for purposes of the Agreement and as of specific dates; were solely for the benefit of the parties to the Agreement; may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made for the purposes of allocating contra

Notes Conversion Agreement, dated as of June 28, 2018, by and among Keryx Biopharmaceuticals, Inc., Baupost Group Securities, L.L.C. and, with respect to certain sections only, Akebia Therapeutics, Inc.

EX-10.1 Exhibit 10.1 NOTES CONVERSION AGREEMENT This Notes Conversion Agreement (this “Conversion Agreement”) is dated as of June 28, 2018, among Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”) (for purposes of Sections 2.3(c), 5.5 (with respect to the last sentence only) and 5.6 – 5.16 only), Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Baupost Group Se

VOTING AGREEMENT

EX-99.1 Exhibit 99.1 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of June 28, 2018, by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (“Keryx”), and the undersigned stockholder (the “Stockholder”) of Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”). WITNESSETH: WHEREAS, Keryx, Akebia and Alpha Therapeutics Merger Sub, Inc., a

VOTING AGREEMENT

EX-99.2 Exhibit 99.2 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of June 28, 2018, by and between Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”), and the undersigned stockholder (the “Stockholder”) of Keryx Biopharmaceuticals, Inc., a Delaware corporation (“Keryx”). WITNESSETH: WHEREAS, Keryx, Akebia and Alpha Therapeutics Merger Sub, Inc., a

Agreement and Plan of Merger, dated as of June 28, 2018, by and among Akebia Therapeutics, Inc., Alpha Therapeutics Merger Sub, Inc., and Keryx Biopharmaceuticals, Inc.*

EX-2.1 The Agreement and Plan of Merger (the “Agreement”) contains representations, warranties and covenants that were made only for purposes of the Agreement and as of specific dates; were solely for the benefit of the parties to the Agreement; may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made for the purposes of allocating contra

VOTING AGREEMENT

EX-99.1 Exhibit 99.1 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of June 28, 2018, by and between Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”), and the undersigned stockholder (the “Stockholder”) of Keryx Biopharmaceuticals, Inc., a Delaware corporation (“Keryx”). WITNESSETH: WHEREAS, Keryx, Akebia and Alpha Therapeutics Merger Sub, Inc., a

AKBA / Akebia Therapeutics, Inc. 8-K (Prospectus)

425 1 d819026d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2018 Akebia Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36352 20-8756903 (State or other jurisdiction of inc

Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease Expects to Capture Significant Operating and Product Port

EX-99.2 Exhibit 99.2 Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease Expects to Capture Significant Operating and Product Portfolio Synergies, Accelerating Revenue Growth and Creating Shareholder Value Consolidates an FDA-Approved Oral CKD Product and an

Notes Conversion Agreement, dated as of June 28, 2018, by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C.

EX-10.1 Exhibit 10.1 NOTES CONVERSION AGREEMENT This Notes Conversion Agreement (this “Conversion Agreement”) is dated as of June 28, 2018, among Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”) (for purposes of Sections 2.3(c), 5.5 (with respect to the last sentence only) and 5.6 – 5.16 only), Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Baupost Group Se

Agreement and Plan of Merger, dated as of June 28, 2018, by and among Akebia Therapeutics, Inc., Alpha Therapeutics Merger Sub Inc. and Keryx Biopharmaceuticals, Inc. *

EX-2.1 The Agreement and Plan of Merger (the “Agreement”) contains representations, warranties and covenants that were made only for purposes of the Agreement and as of specific dates; were solely for the benefit of the parties to the Agreement; may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made for the purposes of allocating contra

VOTING AGREEMENT

EX-99.2 6 d628548dex992.htm EX-99.2 Exhibit 99.2 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of June 28, 2018, by and between Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”), and the undersigned stockholder (the “Stockholder”) of Keryx Biopharmaceuticals, Inc., a Delaware corporation (“Keryx”). WITNESSETH: WHEREAS, Keryx, Akebia and Alpha Ther

Notes Conversion Agreement, dated as of June 28, 2018, by and among Keryx Biopharmaceuticals, Inc., Baupost Group Securities, L.L.C. and, with respect to certain sections only, Akebia Therapeutics, Inc.

EX-10.1 Exhibit 10.1 NOTES CONVERSION AGREEMENT This Notes Conversion Agreement (this “Conversion Agreement”) is dated as of June 28, 2018, among Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”) (for purposes of Sections 2.3(c), 5.5 (with respect to the last sentence only) and 5.6 – 5.16 only), Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Baupost Group Se

Amendment to Amended and Restated Bylaws, dated June 27, 2018.

EX-3.1 Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF KERYX BIOPHARMACEUTICALS, INC. Article 8 of the Amended and Restated Bylaws of Keryx Biopharmaceuticals, Inc. is hereby amended by adding the following new Section 8.06: 8.06 Exclusive Jurisdiction of Delaware Courts. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the

VOTING AGREEMENT

EX-99.1 Exhibit 99.1 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of June 28, 2018, by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (“Keryx”), and the undersigned stockholder (the “Stockholder”) of Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”). WITNESSETH: WHEREAS, Keryx, Akebia and Alpha Therapeutics Merger Sub, Inc., a

Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease Expects to Capture Significant Operating and Product Port

EX-99.3 Exhibit 99.3 Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease Expects to Capture Significant Operating and Product Portfolio Synergies, Accelerating Revenue Growth and Creating Shareholder Value Consolidates an FDA-Approved Oral CKD Product and an

KERX / Keryx Biopharmaceuticals, Inc. 8-K (Prospectus)

425 1 d628548d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Inc

Separation Agreement between Keryx Biopharmaceuticals, Inc. and Mr. Madison, dated June 14, 2018.

EX-10.1 Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is made and entered into by and between Keryx Biopharmaceuticals, Inc. (“Company”) and Gregory P. Madison (“Executive”). WHEREAS, Executive’s employment with Company, Executive’s membership on Company’s Board of Directors (the “Board”) and any committees thereof, and any of Executive’s other roles with Company,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (

KERX / Keryx Biopharmaceuticals, Inc. DEF 14A

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Keryx Biopharmaceuticals Announces Data from an Investigator Sponsored Trial of Ferric Citrate in Patients with Advanced Chronic Kidney Disease in a Late-Breaking Presentation at the 55th Annual ERA/EDTA Today in Copenhagen Conference Call Today at 8

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Data from an Investigator Sponsored Trial of Ferric Citrate in Patients with Advanced Chronic Kidney Disease in a Late-Breaking Presentation at the 55th Annual ERA/EDTA Today in Copenhagen Conference Call Today at 8:30 a.m. EST Copenhagen, Denmark, May 25, 2018 - Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a company focused on bringing inn

Regulation FD Disclosure, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Commis

Amended and Restated License Agreement by and between Panion & BF Biotech, Inc. and Keryx Biopharmaceuticals, Inc. dated March 17, 2008.

Exhibit 10.1 AMENDED & RESTATED LICENSE AGREEMENT THIS AMENDED & RESTATED LICENSE AGREEMENT (the “Agreement”), effective as of this 17th day of March, 2008 (the “Effective Date”), by and between Panion & BF Biotech, Inc., with offices at 16F No. 3, Yuanqu Street, Nangang District, Taipei, Taiwan, ROC (hereinafter "Licensor"), and Keryx Biopharmaceuticals, Inc, with offices at 750 Lexington, 20th F

KERX / Keryx Biopharmaceuticals, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-30929 KERYX BIOPHARMACEUT

Employment Agreement by and between Keryx Biopharmaceuticals, Inc. and Jodie Morrison dated May 10, 2018 (incorporated by reference to Exhibit 10.5 to Keryx Biopharmaceuticals, Inc.’s Quarterly Report on Form 10-Q, filed on May 10, 2018)

EX-10.5 3 keryx-3312018x10qex105.htm EXHIBIT 10.5 Exhibit 10.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this 10th day of May, 2018 (the “Effective Date”) by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Jodie Morrison (“Executive”) (each a “Party” and collectively, the “Parties”). BACKGROUND The Company des

Notes Exchange Agreement dated as of May 8, 2018, between Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C., filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on May 10, 2018 (File No. 000-30929), and incorporated herein by reference.

EX-10.1 EXHIBIT 10.1 Execution Version NOTES EXCHANGE AGREEMENT This Notes Exchange Agreement (this “Exchange Agreement”) is dated as of May 8, 2018, between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Baupost Group Securities, L.L.C., a Massachusetts limited liability company (the “Investor”). WHEREAS, subject to the terms and conditions set forth in the Note Purch

Agenda Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Opening Remarks Jodie Morrison, Interim CEO 1Q 2018 Results Scott Holmes, CFO Commercial Progress Doug Jermasek, VP, Marketing & Str

EX-99.2 6 d579857dex992.htm EX-99.2 Keryx biopharmaceuticals First Quarter 2018 Financial Results Call May 10, 2018 Exhibit 99.2 Agenda Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Opening Remarks Jodie Morrison, Interim CEO 1Q 2018 Results Scott Holmes, CFO Commercial Progress Doug Jermasek, VP, Marketing & Strategy Question & Answ

Indenture dated as of May 9, 2018, between Keryx Biopharmaceuticals, Inc. and The Bank of New York Mellon Trust Company, N.A., filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on May 10, 2018 (File No. 000-30929), and incorporated herein by reference.

EX-10.2 Exhibit 10.2 Execution Version KERYX BIOPHARMACEUTICALS, INC. ZERO COUPON CONVERTIBLE SENIOR NOTES DUE 2021 INDENTURE DATED AS OF MAY 9, 2018 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE TABLE OF CONTENTS PAGE ARTICLE 1 Definitions And Incorporation By Reference 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 11 Section 1.03. Rules of Construction 11 ARTICLE 2

Registration Rights Agreement dated as of May 9, 2018, between Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C., filed as Exhibit 10.3 to the Registrant’s Current Report on Form 8-K, filed on May 10, 2018 (File No. 000-30929), and incorporated herein by reference.

EX-10.3 Exhibit 10.3 Execution Version REGISTRATION RIGHTS AGREEMENT BY AND AMONG KERYX BIOPHARMACEUTICALS, INC. AND BAUPOST GROUP SECURITIES, L.L.C. DATED AS OF MAY 9, 2018 TABLE OF CONTENTS ARTICLE I EFFECTIVENESS 1 Section 1.1. Effectiveness 1 ARTICLE II DEFINITIONS 1 Section 2.1. Definitions 1 Section 2.2. Other Interpretive Provisions 5 ARTICLE III REGISTRATION RIGHTS 5 Section 3.1. Demand Re

Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results

EX-99.1 5 d579857dex991.htm EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results • First quarter 2018 total revenues of $21.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $20.6 million; a 96 percent increase compared to the first quarter of 2017 • Company exchanges its convertible senior notes due 2020 in debt restructuring and fina

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Co

KERX / Keryx Biopharmaceuticals, Inc. / Baupost Group LLC/MA - NONE Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Keryx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 492515101 (CUSIP Number) Seth A. Klarman, The Baupost Group, L.L.C. 10 St. James Avenue, Suite 1700, Boston, Massachusetts 02116 Phone : (617) 210-8300 (Name, Ad

JOINT FILING AGREEMENT

EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule I3d-1 (k)(I) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule I3D (including amendments thereto) with respect to beneficial ownership of shares of Common Stock of Keryx Biopharmaceuticals, Inc.

KERX / Keryx Biopharmaceuticals, Inc. 8-K (Current Report)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Comm

Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue • Gregory Madison resigned as president and chief executive officer of the company and from its board of directors • Jodie Morrison, current Keryx board member, named interim chief executive officer • Company expects to report first quarter 2018 total revenue of $21.0 million -

KERX / Keryx Biopharmaceuticals, Inc. 10-K/A (Annual Report)

10-K/A 1 kerx-12312017x10ka.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to

Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated April 30, 2018.

Exhibit 31.2.2 CERTIFICATIONS I, Scott A. Holmes, certify that: 1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of Keryx Biopharmaceuticals, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such stateme

Certification of Interim Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated April 30, 2018.

Exhibit 31.1.2 CERTIFICATIONS I, Jodie P. Morrison, certify that: 1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of Keryx Biopharmaceuticals, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such state

Master Manufacturing Services and Supply Agreement, dated December 20, 2017, by and between Keryx Biopharmaceuticals, Inc. and Siegfried Evionnaz SA (incorporated by reference to Exhibit 10.13 to Keryx Biopharmaceuticals, Inc.’s Annual Report on Form 10-K, filed on February 21, 2018)

Exhibit 10.13 MASTER MANUFACTURING SERVICES AND SUPPLY AGREEMENT This Master Manufacturing Services and Supply Agreement (this “Agreement”) is entered into as of the date of last signature (the “Agreement Date”), by and between Siegfried Evionnaz SA (together with its Affiliates and subsidiaries, “Vendor”), with principal offices located at Route du Simplon 1, 36, 1902 Evionnaz, Switzerland, and K

Employment Agreement with Gregory P. Madison dated March 10, 2015.

Exhibit 10.14 EMPLOYMENT AGREEMENT BETWEEN GREGORY P. MADISON AND KERYX BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT TABLE OF CONTENTS 1.Effective Date 1 2.Employment 1 3.Employment Period 1 4.Extent of Service 2 5.Compensation and Benefits 2 6.Termination of Employment 4 7.Obligations of the Company upon Termination 7 8.Change in Control 10 9.Non-exclusivity of Rights 11 10.No Mitigation 12 11.M

List of Subsidiaries.

Exhibit 21.1 Keryx Biopharmaceuticals, Inc. List of Subsidiaries Name of Subsidiary State/Jurisdiction of Incorporation ACCESS Oncology, Inc. Delaware Accumin Diagnostics, Inc. Delaware AOI Pharma, Inc. Delaware AOI Pharmaceuticals, Inc. Delaware Neryx Biopharmaceuticals, Inc. Delaware Online Collaborative Oncology Group, Inc. Delaware Keryx Biomedical Technologies Ltd. Israel Keryx (Israel) Ltd.

KERX / Keryx Biopharmaceuticals, Inc. 10-K (Annual Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-30929 KERYX

Product Manufacture and Supply and Facility Construction Agreement, dated December 11, 2017, by and between Keryx Biopharmaceuticals, Inc. and BioVectra Inc.

Exhibit 10.12 PRODUCT MANUFACTURE AND SUPPLY AND FACILITY CONSTRUCTION AGREEMENT Between BIOVECTRA INC. And KERYX BIOPHARMACEUTICALS, INC. This product manufacture and supply and facility construction agreement (“Agreement”) is made and entered into on the date of last signature by and between BioVectra Inc., with its registered offices at 11 Aviation Avenue, Charlottetown, PEI, C1E 0A1, Canada (“

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporatio

KERX / Keryx Biopharmaceuticals, Inc. / ABRAMS CAPITAL MANAGEMENT, L.P. Passive Investment

SC 13G/A 1 schedule13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Keryx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 492515101 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check

KERX / Keryx Biopharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment

keryxbiopharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: Keryx Biopharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 492515101 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2018 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation

Agenda Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Opening Remarks Greg Madison, President & CEO 4Q 2017 Results Scott Holmes, CFO Commercial Progress Doug Jermasek, VP, Marketing & S

EX-99.2 Keryx biopharmaceuticals 4Q and Full Year 2017 Financial Results Call February 7, 2018 Exhibit 99.2 Agenda Copyright ? 2018 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Opening Remarks Greg Madison, President & CEO 4Q 2017 Results Scott Holmes, CFO Commercial Progress Doug Jermasek, VP, Marketing & Strategy Question & Answer All Forward-Look

Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results ? Fourth quarter 2017 total revenues of $18.7 million, including net U.S. Auryxia? (ferric citrate) product sales of $17.3 million ? Full year 2017 total revenues of $60.6 million; net U.S. Auryxia product sales more than doubled in 2017 to $55.5 million, as compared to 2016 BOSTON, MA, Febr

KERX / Keryx Biopharmaceuticals, Inc. FORM 8-K (Current Report)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 20, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporatio

Entry into a Material Definitive Agreement

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 20, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporatio

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporatio

Amended and Restated Bylaws of Keryx Biopharmaceuticals, Inc., adopted on December 13, 2017, filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on December 19, 2017 (File No. 000-30929), and incorporated herein by reference.

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS of KERYX BIOPHARMACEUTICALS, INC. a Delaware Corporation (adopted on December 13, 2017) TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1.01 Registered Office 1 Section 1.02 Principal Office 1 Section 1.03 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 Section 2.01 Annual Meetings 1 Section 2.02 Special Meetings 1 Section 2.03 Place of Meeti

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 11, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Commi

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 20, 2017, is by and among Abrams Capital Partners II L.P., Abrams Capital LLC, Abrams Capital Management LLC, Abrams Capital Management L.P. and David Abrams (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 1

KERX / Keryx Biopharmaceuticals, Inc. / Abrams Capital, Llc - AMENDMENT NO. 2 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Keryx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 492515101 (CUSIP Number) November 10, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi

Agenda Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Today’s Announcements & Importance of Auryxia® Greg Madison, President & CEO 3Q 2017 Results Scott Holmes, CFO Auryxia’s Broad Label

EX-99.2 U.S. FDA approval of Additional Indication for AURYXIA? (ferric citrate) TABLETS Keryx Biopharmaceuticals, Inc 11/7/2017 www.keryx.com Exhibit 99.2 Agenda Copyright ? 2017 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Today?s Announcements & Importance of Auryxia? Greg Madison, President & CEO 3Q 2017 Results Scott Holmes, CFO Auryxia?s Broad

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

8-K 1 d480884d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdic

Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results ? Company reported $15.0 million in third quarter 2017 total revenues, including net U.S. Auryxia? product sales of $13.6 million ? U.S. Food and Drug Administration (FDA) approves Auryxia? (ferric citrate) tablets as a treatment for adults with iron deficiency anemia and chronic kidney disease, not on dia

U.S. FDA Approves Auryxia® (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis

EX-99.3 Exhibit 99.3 U.S. FDA Approves Auryxia? (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis ? Auryxia is the only oral treatment option available today developed and approved specifically for adults living with iron deficiency anemia and chronic kidney disease, not on dialysis ? One in seven adults in the U.S. is living

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30929 KERYX BIOPHARMACE

Amended and Restated Sub-License Agreement, dated June 8, 2009, as amended by the First Amendment thereto, dated June 12, 2013, by and between Keryx Biopharmaceuticals, Inc., Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd (incorporated by reference to Exhibit 10.1 to Keryx Biopharmaceuticals, Inc.’s Quarterly Report on Form 10-Q

EX-10.1 2 kerx-9302017x10qex101.htm EXHIBIT 10.1 AMENDED AND RESTATED SUBLICENSE AGREEMENT THIS AMENDED AND RESTATED SUBLICENSE AGREEMENT (the “Agreement”), effective this 8th day of June, 2009 (the “Effective Date”), by and between KERYX BIOPHARMACEUTICALS, INC., with offices at 750 Lexington Avenue, 20th Floor, New York, NY 10022, U.S.A. (“Keryx” or “Sublicensor”) and JAPAN TOBACCO INC., with of

Product Agreement, dated August 29, 2017, by and between Keryx Biopharmaceuticals, Inc. and Patheon Inc. (an affiliate of Patheon Manufacturing Services LLC) related to the Master Manufacturing Services Agreement by and between Keryx Biopharmaceuticals, Inc. and Patheon Manufacturing Services LLC and certain of its affiliates dated November 12, 2016 (incorporated by reference to Exhibit 10.2 to Keryx Biopharmaceuticals, Inc.’s Quarterly Report on Form 10-Q

WHITBY PRODUCT AGREEMENT (Ferric Citrate IR Tablets) This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated September 27, 2016 between Patheon Manufacturing Services LLC and Keryx BioPharmaceuticals, Inc.

EX-24

SECTION 16 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Brian Adams, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder; (2) do and perform any and all

Keryx Biopharmaceuticals Announces Changes to its Board of Directors

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Changes to its Board of Directors ? Mark Enyedy appointed to Keryx?s board of directors ? Current Keryx board member Michael Rogers appointed chairman BOSTON, MA, September 13, 2017 ? Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announc

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporatio

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 29, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation)

KERX / Keryx Biopharmaceuticals, Inc. ESP

CORRESP Daniel T. Kajunski | 617 348 1715 | [email protected] One Financial Center Boston, MA 02111 617-542-6000 617-542-2241 fax www.mintz.com August 25, 2017 VIA EDGAR & FEDEX Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director Irene Paik Re: Keryx Biopharmaceuticals, Inc. Form 10-K Filed Mar

Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 27, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Commi

Up to $75,000,000 Common Stock

424B5 1 d423202d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-214513 PROSPECTUS SUPPLEMENT (To prospectus dated December 6, 2016) Up to $75,000,000 Common Stock In accordance with the terms of the Controlled Equity OfferingSM sales agreement, dated November 9, 2016, we entered into with Cantor Fitzgerald & Co., we may offer and sell shares of our common st

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 27, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (

Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance ? Company reported $15.1 million in second quarter 2017 total revenues, including net U.S. Auryxia? (ferric citrate) product sales of $14.1 million, a 71 percent increase compared to the second quarter of 2016 ? Full year 2017 net U.S Auryxia product sales gu

Agenda – Second Quarter 2017 Financial Results Topic Speakers Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President & CEO 2017 Guidance/2Q’17 Results Scott Holmes, SVP & CFO Maximizing Auryxia® Doug Jermasek, V

EX-99.2 Keryx Biopharmaceuticals, Inc. Second Quarter 2017 Financial Results July 27, 2017 Building a Leading Renal Company Exhibit 99.2 Agenda ? Second Quarter 2017 Financial Results Topic Speakers Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President & CEO 2017 Guidance/2Q?17 Results Scott Holmes, SVP & CFO Maximizing Auryxia? Doug Jermasek, VP, Marketing

Amendment to Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., dated June 13, 2017, filed as Exhibit 3.6 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed on July 27, 2017 (File No. 000-30929), and incorporated herein by reference.

Exhibit 3.6 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KERYX BIOPHARMACEUTICALS, INC. Keryx Biopharmaceuticals, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law (the “Corporation”), does hereby certify: FIRST: That on March 21, 2017, the Board of Directors of the Corporation adopted resolutions setting fort

Certificate of Validation of the filing and effectiveness of the Amendment to Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., dated June 13, 2017, filed as Exhibit 3.5 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed on July 27, 2017 (File No. 000-30929), and incorporated herein by reference.

Exhibit 3.5 CERTIFICATE OF VALIDATION OF KERYX BIOPHARMACEUTICALS, INC. Pursuant to Section 204 of the General Corporation Law of the State of Delaware Keryx Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies as follows: 1. The defective corporate act that is the subject of this Certificate of Validation is the fili

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30929 KERYX BIOPHARMACEUTICA

Submission of Matters to a Vote of Security Holders

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (C

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Co

Agenda – First Quarter 2017 Financial Results Topic Speakers Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President and CEO 2017 Guidance & 1Q’17 Financial Results Scott Holmes, SVP and CFO Drivers of Recent Gro

EX-99.2 Keryx Biopharmaceuticals, Inc. First Quarter 2017 Financial Results May 4, 2017 Building a Leading Renal Company Exhibit 99.2 Agenda ? First Quarter 2017 Financial Results Topic Speakers Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President and CEO 2017 Guidance & 1Q?17 Financial Results Scott Holmes, SVP and CFO Drivers of Recent Growth Tony Chamber

Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results

EX-99.1 2 d392831dex991.htm EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results • Company reported $11.8 million in first quarter 2017 total revenue, including net U.S. Auryxia® (ferric citrate) product sales of $10.5 million • Provides 2017 net U.S Auryxia product sales guidance of $56 to $60 million • Target action date of November 6, 2017 set for supplem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30929 KERYX BIOPHARMACEUTIC

Keryx Biopharmaceuticals DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pro

Keryx Biopharmaceuticals DEF 14A

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 10, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Commissi

First Supplemental Indenture, dated as of April 10, 2017, by and among Keryx Biopharmaceuticals, Inc., The Bank of New York Mellon Trust Company, N.A. and the note holder signatory thereto, to the Indenture, dated as of October 15, 2015, filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on April 10, 2017 (File No. 000-30929), and incorporated herein by reference.

EX-10.1 Exhibit 10.1 EXECUTION VERSION FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE (this ?First Supplemental Indenture?), dated as of April 10, 2017, among KERYX BIOPHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a national banking association, as Trustee under the Indenture referred to below (in such capacity, the ?Trus

Keryx Biopharmaceuticals PRE 14A

PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (

Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results ? Fourth quarter and Full Year 2016 Auryxia? (ferric citrate) net U.S. product sales of $8.2 million and $27.2 million, respectively ? Early 2017 Auryxia prescription demand showing positive momentum and outperformed overall phosphate binder market in January BOSTON, MA, March 1, 2017 ? Kery

Agenda - Fourth Quarter and Full Year 2016 Financial Results Topic Speaker Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President and CEO Financial Results Scott Holmes, SVP and CFO Near-term Opportunities and O

EX-99.2 Keryx Biopharmaceuticals, Inc. Fourth Quarter and Full Year 2016 Financial Results March 1, 2017 Building a Leading Renal Company Exhibit 99.2 Agenda - Fourth Quarter and Full Year 2016 Financial Results Topic Speaker Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President and CEO Financial Results Scott Holmes, SVP and CFO Near-term Opportunities and

Master Manufacturing Services Agreement by and between Keryx Biopharmaceuticals, Inc. and Patheon Manufacturing Services LLC and certain of its affiliates, dated September 27, 2016, and related Product Agreement dated September 27, 2016, and related Product Agreement dated October 12, 2016 (incorporated by reference to Exhibit 10.12 to Keryx Biopharmaceuticals, Inc.’s Annual Report on Form 10-K, filed on March 1, 2017)

Master Manufacturing Services Agreement Confidential Materials Omitted, Designated Herein as [***], and Filed Separately with the Securities and Exchange Commission Master Manufacturing Services Agreement September 27, 2016 Table of Contents ARTICLE 14 STRUCTURE OF AGREEMENT AND INTERPRETATION4 1.

Keryx Biopharmaceuticals, Inc. List of Subsidiaries

EX-21.1 7 ex211201610k.htm EXHIBIT 21.1 Exhibit 21.1 Keryx Biopharmaceuticals, Inc. List of Subsidiaries Name of Subsidiary State/Jurisdiction of Incorporation ACCESS Oncology, Inc. Delaware Accumin Diagnostics, Inc. Delaware AOI Pharma, Inc. Delaware AOI Pharmaceuticals, Inc. Delaware Neryx Biopharmaceuticals, Inc. Delaware Online Collaborative Oncology Group, Inc. Delaware Keryx Biomedical Techn

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-30929 KERYX

One Marina Park Drive Office Lease dated April 29, 2015, by and between Keryx Biopharmaceuticals, Inc. and Fallon Cornerstone One MPD LLC (incorporated by reference to Exhibit 10.29 to Keryx Biopharmaceuticals, Inc.’s Annual Report on Form 10-K, filed on March 1, 2017)

ONE MARINA PARK DRIVE OFFICE LEASE THIS LEASE (this “Lease”), made as of April 29, 2015, by and between FALLON CORNERSTONE ONE MPD LLC, a Delaware limited liability company (“Landlord”), and KERYX BIOPHARMACEUTICALS, INC.

Second Amendment to Employment Agreement with Brian Adams dated December 15, 2016, filed as Exhibit 10.21 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017 (File No. 000-30929), and incorporated herein by reference.

AMENDMENT TWO TO EMPLOYMENT AGREEMENT This Amendment Number Two (the “Amendment”) to the Employment Agreement dated April 8, 2014, as amended by Amendment Number One to the Employment Agreement dated October 15, 2015 (the Employment Agreement, as amended, referred to herein as the “Employment Agreement”) is made and entered into this 15th day of December, 2016 by and between Keryx Biopharmaceuticals, Inc.

Second Amendment to Employment Agreement with John F. Neylan, M.D. dated January 6, 2017, filed as Exhibit 10.23 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017 (File No. 000-30929), and incorporated herein by reference.

AMENDMENT TWO TO EMPLOYMENT AGREEMENT This Amendment Number Two (the ?Amendment?) to the Employment Agreement dated April 22, 2015, as amended by Amendment Number One to the Employment Agreement dated October 15, 2015 (the Employment Agreement, as amended, referred to herein as the ?Employment Agreement?) is made and entered into this 6th day of January, 2017 by and between Keryx Biopharmaceuticals, Inc.

Second Amendment to Employment Agreement with Scott Holmes dated January 6, 2017, filed as Exhibit 10.22 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017 (File No. 000-30929), and incorporated herein by reference.

EX-10.22 4 ex1022201610k.htm EXHIBIT 10.22 AMENDMENT TWO TO EMPLOYMENT AGREEMENT This Amendment Number Two (the “Amendment”) to the Employment Agreement dated June 26, 2015, as amended by Amendment Number One to the Employment Agreement dated October 15, 2015 (the Employment Agreement, as amended, referred to herein as the “Employment Agreement”) is made and entered into this 6th day of January, 2

Keryx Biopharmaceuticals 3G/A (Passive Acquisition of More Than 5% of Shares)

SC 13G/A 1 kerx123116a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Keryx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 492515101 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropr

Keryx Biopharmaceuticals 3G/A (Passive Acquisition of More Than 5% of Shares)

keryxbiopharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Keryx Biopharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 492515101 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check

EX-24

Exhibit 24 SECTION 16 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Brian Adams, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder; (2) do and perform a

Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference ? Enters 2017 with positive momentum for Auryxia? (ferric citrate) in Dialysis; preliminary unaudited fourth quarter net U.S. product sales of $8.2 million ? Submitted supplemental new drug application (sNDA) seeking Auryxia label expansio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2017 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation)

Employment Agreement with Christine A. Carberry dated January 6, 2017, filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on January 9, 2017 (File No. 000-30929), and incorporated herein by reference.

EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT BETWEEN CHRISTINE A. CARBERRY AND KERYX BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT 1. Effective Date 1 2. Employment 1 3. Employment Period 1 4. Extent of Service 2 5. Compensation and Benefits 2 (a) Base Salary 2 (b) Incentive, Savings and Retirement Plans 2 (c) Welfare Benefit Plans 3 (d) Expenses 3 (e) Vacation 3 6. Termination of Employment 4 (a) De

Disclaimers Forward-looking Statements Some of the statements included in this presentation, particularly those regarding expected revenues, the commercialization and ongoing clinical development of Auryxia and the expected impact of the new members

EX-99.2 Greg Madison President & Chief Executive Officer Keryx Biopharmaceuticals, Inc. 35th Annual J.P. Morgan Healthcare Conference January 9 ? 11, 2017 Building a Leading Renal Company Exhibit 99.2 Disclaimers Forward-looking Statements Some of the statements included in this presentation, particularly those regarding expected revenues, the commercialization and ongoing clinical development of

Keryx Biopharmaceuticals ESP

CORRESP KERYX BIOPHARMACEUTICALS, INC. One Marina Park Drive, 12th Floor Boston, MA 02210 December 2, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director Johnny Gharib Erin Jaskot Re: Keryx Biopharmaceuticals, Inc. Registration Statement on Form S-3 Filed on November 9, 2016, as ame

Keryx Biopharmaceuticals AMENDMENT NO. 1 TO FORM S-3

Amendment No. 1 to Form S-3 Table of Contents As filed with the Securities and Exchange Commission on November 30, 2016 Registration No. 333-214513 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KERYX BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 1

Keryx Biopharmaceuticals ESP

Daniel T. Kajunski | 617 348 1715 | [email protected] One Financial Center Boston, MA 02111 617-542-6000 617-542-2241 fax www.mintz.com November 30, 2016 VIA EDGAR & FEDEX Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes, Assistant Director Johnny Gharib Erin Jaskot Re: Keryx Biopharmaceuticals, Inc. Registratio

Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation

Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update

EX-99.1 2 d286746dex991.htm EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update • The company has established adequate supply of Auryxia®(ferric citrate) and is prepared to make this medicine available to people on dialysis pending U.S. FDA approval of second contract manufacturer • Keryx has completed the sNDA (supplemental ne

Third Quarter 2016 Financial Results - Agenda Topic Speaker Introduction Amy Sullivan, VP Strategic Operations and Corporate Affairs Opening Remarks Greg Madison, President and CEO Third Quarter Financial Results Scott Holmes, Chief Financial Officer

EX-99.2 Third Quarter 2016 Financial Results Conference Call November 9, 2016 Keryx Biopharmaceuticals, Inc. Exhibit 99.2 Safe Harbor Statement Some of the statements included in this presentation, particularly those regarding future revenues and expenses and the commercialization and ongoing clinical development of Auryxia, including those statements related to the interruption in the supply of A

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation

Form of Indemnification Agreement between Keryx Biopharmaceuticals, Inc. and its directors and officers, filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed on November 9, 2016 (File No. 000-30929), and incorporated herein by reference.

EX-10.1 Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement, dated as of [ ] (this “Agreement”), is made by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”). RECITALS: A. The Corporation recognizes that competent and experienced persons may be reluctant to serve or to continue to serve as directors or officers of corporati

As filed with the Securities and Exchange Commission on November 9, 2016

Form S-3 Table of Contents As filed with the Securities and Exchange Commission on November 9, 2016 Registration No.

KERYX BIOPHARMACEUTICALS, INC. [ ] Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.

EX-4.9 Exhibit 4.9 KERYX BIOPHARMACEUTICALS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04

Controlled Equity OfferingSM Sales Agreement dated November 9, 2016, by and between Keryx Biopharmaceuticals, Inc. and Cantor Fitzgerald & Co., filed as Exhibit 1.2 to the Registrant's Registration Statement on Form S-3, filed on November 9, 2016 (File No. 333-214513), and incorporated herein by reference.

EX-1.2 Exhibit 1.2 KERYX BIOPHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement November 9, 2016 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

KERYX BIOPHARMACEUTICALS, INC. [ ] Trustee Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13

EX-4.10 Exhibit 4.10 KERYX BIOPHARMACEUTICALS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 12, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Commi

Safe Harbor Statement Various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Importa

EX-99.1 Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, Inc. September 7, 2016 Exhibit 99.1 Safe Harbor Statement Various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Important factors may cause our actual results to differ

Keryx Biopharmaceuticals S-8

S-8 As filed with the Securities and Exchange Commission on August 23, 2016 Registration No.

Keryx Biopharmaceuticals S-8

S-8 As filed with the Securities and Exchange Commission on August 23, 2016 Registration No.

Amendment to Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc., dated May 25, 2016, filed as Exhibit 3.4 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed on August 5, 2016 (File No. 000-30929), and incorporated herein by reference.

EX-3.4 2 d222301dex34.htm EX-3.4 EXHIBIT 3.4 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KERYX BIOPHARMACEUTICALS, INC. Keryx Biopharmaceuticals, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law (the “Corporation”), does hereby certify: FIRST: That on April 1, 2016, the Board of Directors of the Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

10-Q 1 d222301d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation)

Keryx Biopharmaceuticals Announces Interruption in Supply of Auryxia® (ferric citrate) and Second Quarter 2016 Financial Results - Supply interruption does not affect the safety profile of currently available Auryxia - - Company withdraws its 2016 fi

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Interruption in Supply of Auryxia? (ferric citrate) and Second Quarter 2016 Financial Results - Supply interruption does not affect the safety profile of currently available Auryxia - - Company withdraws its 2016 financial guidance - - Company to host conference call today at 8:30 a.m. EDT - BOSTON, MA, August 1, 2016 ? Keryx Biopharmaceutica

EX-24

SECTION 16 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Brian Adams, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder; (2) do and perform any and all

EX-24

SECTION 16 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Brian Adams, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder; (2) do and perform any and all

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2016 Keryx Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporatio

KERX / Keryx Biopharmaceuticals, Inc. / Baupost Group LLC/MA - NONE Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Keryx Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 492515101 (CUSIP Number) Seth A. Klarman, The Baupost Group, L.L.C. 10 St. James Avenue, Suite 1700, Boston, Massachusetts 02116 Phone : (617) 210-8300 (Name, Ad

Keryx Biopharmaceuticals, Inc. Fourth Amended and Restated Directors Equity Compensation Plan (incorporated by reference to Exhibit 10.2 to Keryx Biopharmaceuticals, Inc.’s Current Report on Form 8-K

EX-10.2 3 d199697dex102.htm EX-10.2 Exhibit 10.2 KERYX BIOPHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED DIRECTORS EQUITY COMPENSATION PLAN ARTICLE 1 PURPOSE 1.1. PURPOSE. The purpose of the Keryx Biopharmaceuticals, Inc. Fourth Amended and Restated Directors Equity Compensation Plan is to attract, retain and compensate highly-qualified individuals who are not employees of Keryx Biopharmaceutic

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (C

Keryx Biopharmaceuticals, Inc. Amended and Restated 2013 Incentive Plan (incorporated by reference to Exhibit 10.1 to Keryx Biopharmaceuticals, Inc.’s Current Report on Form 8-K, filed on May 27, 2016)

EX-10.1 Exhibit 10.1 KERYX BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED 2013 INCENTIVE PLAN KERYX BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED 2013 INCENTIVE PLAN ARTICLE 1 PURPOSE 4 1.1 General 4 ARTICLE 2 DEFINITIONS 4 2.1 Definitions 4 ARTICLE 3 EFFECTIVE TERM OF PLAN 9 3.1 Effective Date 9 3.2 Term of Plan 9 ARTICLE 4 ADMINISTRATION 9 4.1 Committee 9 4.2 Actions and Interpretations by the Co

Safe Harbor Statement Various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Importa

EX-99.2 First Quarter 2016 Financial Results April 28, 2016 Keryx Biopharmaceuticals, Inc. Exhibit 99.2 Safe Harbor Statement Various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Important factors may cause our actual results to dif

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation)

Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results

Exhibit 99.1 Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results • Company reported $6.8 million in first quarter total revenues, including $5.6 million of Auryxia™ (ferric citrate) net U.S. product sales • 2016 product sales and cash operating expense guidance reiterated • Company on track to submit supplemental new drug application (sNDA) in the third quarter of 2016 seeking

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Keryx Biopharmaceuticals DEFA14A

DEFA14A 1 d132089ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule

Keryx Biopharmaceuticals DEF 14A

DEF 14A 1 d131732ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as

Keryx Biopharmaceuticals PRE 14A

PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors BOSTON, MA, April 1, 2016 ? Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced appointment of two industry leaders to Keryx?s board of directors, which increases the s

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation)

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation)

Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease ? Registration trial demonstrated statistically significant differences versus placebo for the primary and all pre-specified secondary endpoints ? Majority of patients

Keryx Biopharmaceuticals FORM S-8

Form S-8 As filed with the Securities and Exchange Commission on March 11, 2016 Registration No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporation) (Commissi

Keryx Biopharmaceuticals, Inc. List of Subsidiaries Name of Subsidiary State/Jurisdiction of Incorporation ACCESS Oncology, Inc. Delaware Accumin Diagnostics, Inc. Delaware AOI Pharma, Inc. Delaware AOI Pharmaceuticals, Inc. Delaware Neryx Biopharmac

EX-21.1 Exhibit 21.1 Keryx Biopharmaceuticals, Inc. List of Subsidiaries Name of Subsidiary State/Jurisdiction of Incorporation ACCESS Oncology, Inc. Delaware Accumin Diagnostics, Inc. Delaware AOI Pharma, Inc. Delaware AOI Pharmaceuticals, Inc. Delaware Neryx Biopharmaceuticals, Inc. Delaware Online Collaborative Oncology Group, Inc. Delaware Keryx Biomedical Technologies Ltd. Israel Keryx (Israe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Safe Harbor Statement Various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Importa

EX-99.2 Fourth Quarter and Year End 2015 Financial Results February 25, 2016 Keryx Biopharmaceuticals, Inc. Exhibit 99.2 Safe Harbor Statement Various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Important factors may cause our actu

Keryx Biopharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2016 Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-30929 13-4087132 (State or Other Jurisdiction of Incorporatio

Keryx Biopharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results - Fourth quarter Auryxia net U.S. product sales of $4.8 million – - Keryx provides 2016 Auryxia net U.S. product sales guidance of $31 - $34 million – - Company on

EX-99.1 Exhibit 99.1 Keryx Biopharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results - Fourth quarter Auryxia net U.S. product sales of $4.8 million ? - Keryx provides 2016 Auryxia net U.S. product sales guidance of $31 - $34 million ? - Company on track to provide pivotal phase 3 data for iron deficiency anemia (IDA) in adults with pre-dialysis chronic kidney disease in earl

KERX / Keryx Biopharmaceuticals, Inc. / ABRAMS CAPITAL MANAGEMENT, L.P. - SCHEDULE 13G HOLDINGS REPORT Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Keryx Biopharmaceuticals, Inc.

KERX / Keryx Biopharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment

SC 13G/A 1 keryxbiopharmaceuticalsinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Keryx Biopharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 492515101 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check the appropriate box to designate